# Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Study · id `cardio:ct-nct01601704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01601704](<https://clinicaltrials.gov/study/NCT01601704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01601704

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 8910 participants.

## Technical summary

Registry record NCT01601704. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2017-02-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 8910 participants (enrolled count; ClinicalTrials.gov record NCT01601704, source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)
- Start date: 2012-06 (registry gives no type) (ClinicalTrials.gov record NCT01601704, source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)
- Primary completion: 2015-08 (actual) (ClinicalTrials.gov record NCT01601704, source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)
- Completion: 2015-08 (actual) (ClinicalTrials.gov record NCT01601704, source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)
- Results first posted: 2017-02-27 (ClinicalTrials.gov record NCT01601704, source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01601704, source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01601704-2017-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
- Condition: Obesity
- Condition: Overweight
- Intervention (Drug): NB32
- Intervention (Drug): PBO
- Intervention (Behavioral): Weight Management Program
- Lead sponsor: Orexigen Therapeutics, Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial (`cardio:pubmed-26954408`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c675f911d54df38328587ff57174eb2d4c494e620d2de3d23f5c451b7b469a49
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
